Numaswitch: an efficient high-titer expression platform to produce peptides and small proteins

Abstract The production of peptides as active pharmaceutical ingredients (APIs) by recombinant technologies is emerging interest. A reliable platform, however, still missing due the inherent characteristics such proteolytic sensitivity, aggregation and cytotoxicity. We have developed a new technology named Numaswitch solving present limitations. was successfully employed for diverse small proteins varying in length, physicochemical functional characteristics, including Teriparatide, Linaclotide, human ?-amyloid Serum amyloid A3. Additionally, potential cost-efficient commercial demonstrated yielding > 2 g Teriparatide per liter fermentation broth quality meeting API standard.